Lyell Immunopharma Inc Cash Flow-to-Debt Ratio
Lyell Immunopharma Inc cash flow-to-debt ratio. Lyell Immunopharma Inc (LYEL) has a Cash Flow-to-Debt Ratio of -0.44x as of June 2026, meaning its operating cash flow of $-33.92 Million could theoretically repay 0% of its total liabilities ($77.34 Million) in one year. See financial agility of Lyell Immunopharma Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Lyell Immunopharma Inc (2019–2025)
Cash flow-to-debt ratio of Lyell Immunopharma Inc from 2019 to 2025. Historical debt coverage capacity for Lyell Immunopharma Inc across 7 annual periods. Check Lyell Immunopharma Inc (LYEL) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Lyell Immunopharma Inc Cash Flow-to-Debt Ratio by Year (2019–2025)
Lyell Immunopharma Inc cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Lyell Immunopharma Inc. For the full cash flow conversion analysis, see cash flow conversion of Lyell Immunopharma Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.63x | $-150.02 Million | $91.85 Million | ▼ -8.7% |
| 2024 | -1.50x | $-162.39 Million | $108.03 Million | ▲ +12.7% |
| 2023 | -1.72x | $-163.69 Million | $95.08 Million | ▼ -5.9% |
| 2022 | -1.63x | $-169.56 Million | $104.31 Million | ▼ -154.4% |
| 2021 | -0.64x | $-126.25 Million | $197.62 Million | ▲ +24.6% |
| 2020 | -0.85x | $-160.87 Million | $189.84 Million | ▼ -416.8% |
| 2019 | 0.27x | $39.47 Million | $147.58 Million | — |